Healthcare / Drug Manufacturers - Specialty & GenericNSE
$1411.30
+67.20 (+5.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $683.7M · quality 72.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
79/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18.9B
P/E
18.4x
↓EV/EBITDA
11.7x
↓ROE
15.5%
↑Gross Margin
49.7%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+11.6%
FCF CAGR
+60.0%
FCF margin
15.3%
FCF / Net income
1.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.70B · net income $1.03B · FCF $1.18B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.70B | $7.70B | $6.53B | $5.91B | $5.53B |
| Net Income | $1.03B | $1.03B | $453.1M | $284.9M | $265.7M |
| EBITDA | $1.60B | $1.60B | $944.0M | $711.8M | $703.5M |
| EPS | 76.89 | 76.89 | 33.89 | 21.31 | 19.88 |
| Gross Margin | 49.7% | 49.7% | 42.0% | 36.9% | 37.6% |
| Operating Margin | 15.8% | 15.8% | 7.1% | 5.6% | 5.0% |
| Net Margin | 13.4% | 13.4% | 6.9% | 4.8% | 4.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.00 | 0.08 | 0.09 |
| Current Ratio | 2.44 | 2.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.18B | $1.18B | $683.7M | $237.7M | $288.1M |
| Returns | |||||
| ROE | 15.5% | 15.5% | 8.1% | 5.8% | 5.8% |
| Valuation | |||||
| P/E | 18.36 | 18.36 | 9.20 | 16.20 | 6.43 |
| EV/EBITDA | 11.72 | 11.72 | 3.82 | 6.37 | 2.73 |
| P/B | 2.84 | 2.84 | 0.74 | 0.95 | 0.37 |
| Growth & Yield | |||||
| Revenue Growth | 17.9% | 17.9% | 10.4% | 6.9% | — |
| EPS Growth | 126.9% | 126.9% | 59.0% | 7.2% | — |
| Dividend Yield | 0.7% | 0.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
17.7%
EPS terminal req.
$125.23
Spread vs growth
109.2%
5Y implied EPS CAGR
14.5%
EPS terminal req.
$151.53
Spread vs growth
112.3%
10Y implied EPS CAGR
12.2%
EPS terminal req.
$244.04
Spread vs growth
114.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+251.2%
Start / end P/E
11.9x → 18.4x
EPS bridge
33.89 → 76.89
Residual
+69.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.